相似文献
1
[Fluoroquinolones].
Mikrobiyol Bul. 1987 Apr;21(2):151-7.
2
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
Antimicrob Agents Chemother. 1985 Nov;28(5):716-21. doi: 10.1128/AAC.28.5.716.
3
Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S83-9.
4
Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
Drugs. 1987;34 Suppl 1:159-69. doi: 10.2165/00003495-198700341-00034.
5
Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
Eur J Clin Microbiol. 1987 Apr;6(2):179-82. doi: 10.1007/BF02018204.
6
[In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
Pathol Biol (Paris). 1988 May;36(5):496-9.
7
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):800-4.
8
In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
Infection. 1986 May-Jun;14(3):142-4. doi: 10.1007/BF01643481.
9
Clinical uses of nalidixic acid analogues: the fluoroquinolones.
Eur J Clin Microbiol. 1986 Apr;5(2):138-40. doi: 10.1007/BF02013968.
10
Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
J Antimicrob Chemother. 1987 May;19(5):605-9. doi: 10.1093/jac/19.5.605.
Zotero 插件